<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03763747</url>
  </required_header>
  <id_info>
    <org_study_id>VP-0730</org_study_id>
    <nct_id>NCT03763747</nct_id>
  </id_info>
  <brief_title>Scoreflex NC - Scoring PTCA Catheter</brief_title>
  <official_title>Scoreflex NC - Scoring PTCA Catheter: A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Safety and Device Procedural Success of the Scoreflex NC Scoring PTCA Catheter in Subjects With Stenotic Coronary Arteries During Percutaneous Coronary Intervention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrbusNeich</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinLogix. LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OrbusNeich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open label, multi-center, single arm, observational study designed to evaluate&#xD;
      the acute safety and device procedural success of the Scoreflex NC Scoring Percutaneous&#xD;
      Transluminal Coronary Angioplasty (PTCA) catheters in subjects with stenotic coronary&#xD;
      arteries during percutaneous coronary intervention.&#xD;
&#xD;
      Two-hundred (200) subjects will be treated at up to 15 U.S. sites with the Scoreflex NC&#xD;
      Scoring PTCA catheter during their index procedure. All subjects will be screened according&#xD;
      to the protocol inclusion and exclusion criteria and will be followed through hospital&#xD;
      discharge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2019</start_date>
  <completion_date type="Actual">December 27, 2019</completion_date>
  <primary_completion_date type="Actual">December 27, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Device Procedural Success</measure>
    <time_frame>Peri-procedural (at Day 0)</time_frame>
    <description>Device procedural success consisting of the following:&#xD;
Successful delivery, inflation, deflation, and withdrawal of the study balloon&#xD;
No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in Thrombolysis In Myocardial Infarction (TIMI) flow from baseline as related to the Scoreflex NC study balloon&#xD;
Final TIMI flow grade of 3 at the conclusion of the percutaneous coronary intervention (PCI) procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Angiographic Procedural Success</measure>
    <time_frame>Peri-procedural (at Day 0)</time_frame>
    <description>Angiographic Procedural Success defined as Final diameter stenosis ≤ 50% in at least one of the Scoreflex NC attempted lesions following completion of the interventional procedure, including adjunctive stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Endpoints will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
    <description>In-hospital Major Adverse Cardiac Events (MACE), a composite of:&#xD;
All death (cardiac and non-cardiac)&#xD;
Myocardial infarction (MI)&#xD;
Target Lesion Revascularization (TLR), clinically indicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel</measure>
    <time_frame>Endpoint will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
    <description>In-hospital stent thrombosis (ST) within the Target Vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention)</measure>
    <time_frame>Endpoint will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
    <description>Clinically Significant Arrhythmias (Requiring Intervention)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Scoreflex NC Scoring Catheters That Had Occurrence of Balloon Rupture</measure>
    <time_frame>Peri-procedural</time_frame>
    <description>Occurrence of Scoreflex NC Study Balloon rupture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Had Improvement in Minimum Lumen Diameter (MLD) Following Use of Scoreflex NC Catheter (Measured by Quantitative Coronary Angiography (QCA))</measure>
    <time_frame>Peri-procedural</time_frame>
    <description>Improvement in Minimum Lumen Diameter (MLD) following use of Scoreflex NC catheter (measured by QCA).&#xD;
Improvement in MLD is defined as MLD post use of Scoreflex as greater than MLD from baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Heart Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Scoreflex NC Scoring PTCA Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Scoreflex NC Scoring PTCA catheter</intervention_name>
    <description>To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
    <arm_group_label>Scoreflex NC Scoring PTCA Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Clinical Inclusion Criteria&#xD;
&#xD;
          1. Subject is ≥ 18 years of age.&#xD;
&#xD;
          2. Subject or a legally authorized representative must provide written informed consent&#xD;
             prior to any study related procedures.&#xD;
&#xD;
          3. Subject must agree not to participate in any other clinical study during&#xD;
             hospitalization for the index procedure that would interfere with the endpoints of&#xD;
             this study.&#xD;
&#xD;
          4. Subjects must have a single or double vessel coronary artery disease (CAD) and&#xD;
             clinical evidence of ischemic heart disease, such as CAD, stable / unstable angina or&#xD;
             silent ischemia.&#xD;
&#xD;
             Angiographic Inclusion Criteria&#xD;
&#xD;
          5. Subject must have de novo or restenotic lesion(s) in native coronary arteries,&#xD;
             including in-stent restenosis suitable for percutaneous coronary intervention.&#xD;
&#xD;
          6. A maximum of two lesions, including at least one target lesion, in up to two coronary&#xD;
             arteries.&#xD;
&#xD;
          7. Target lesion must have a reference vessel diameter (RVD) between 1.75 and 4.0 mm by&#xD;
             visual estimation.&#xD;
&#xD;
          8. Target lesion(s) must have a diameter stenosis of ≥70% by visual estimation and may&#xD;
             include chronic total occlusions (CTO).&#xD;
&#xD;
          9. The non-target lesion must be located in different coronary artery from the Target&#xD;
             lesion.&#xD;
&#xD;
         10. Treatment of non-target lesion, if any, must be completed prior to treatment of target&#xD;
             lesion and must be deemed a clinical angiographic success as visually assessed by the&#xD;
             physician.&#xD;
&#xD;
        Clinical Exclusion Criteria:&#xD;
&#xD;
          1. Subject with a known hypersensitivity or contraindication to aspirin, heparin,&#xD;
             bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot&#xD;
             be adequately pre-medicated.&#xD;
&#xD;
          2. Subject with known diagnosis of STEMI or NSTEMI at index presentation or within 7 days&#xD;
             of study screening.&#xD;
&#xD;
          3. Subject with known pregnancy or is nursing. Women of child-bearing potential should&#xD;
             have a documented negative pregnancy test within 7 days before index procedure.&#xD;
&#xD;
          4. Planned or actual target lesion treatment with an unapproved device, atherectomy,&#xD;
             laser, cutting balloon or thrombectomy during the index procedure.&#xD;
&#xD;
          5. A serum creatinine level &gt; 2.0 mg/dl within 7 days prior to index procedure.&#xD;
&#xD;
          6. Cerebrovascular accident (CVA) within the past 6 months.&#xD;
&#xD;
          7. Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.&#xD;
&#xD;
          8. Subject has a known left ventricular ejection fraction (LVEF) &lt;30% (LVEF may be&#xD;
             obtained at the time of the index procedure if the value is unknown, if necessary)&#xD;
&#xD;
          9. Target lesion located within an arterial or saphenous vein graft or graft anastomosis&#xD;
&#xD;
             Angiographic Exclusion Criteria&#xD;
&#xD;
         10. More than two lesions requiring treatment.&#xD;
&#xD;
         11. Target lesion longer than 30 mm by visual estimation.&#xD;
&#xD;
         12. Extreme angulation (90º or greater) proximal to or within the target lesion.&#xD;
&#xD;
         13. Previous percutaneous intervention of lesions in a target vessel (including side&#xD;
             branches) conducted within 9 months before the study procedure and located within 10&#xD;
             mm from the current target lesion.&#xD;
&#xD;
         14. Target lesion demonstrating severe dissection prior to planned deployment of the&#xD;
             Scoreflex NC device&#xD;
&#xD;
         15. Unprotected left main coronary artery disease. (Greater than 50% diameter stenosis)&#xD;
&#xD;
         16. Coronary artery spasm of the target vessel in the absence of a significant stenosis.&#xD;
&#xD;
         17. Target lesion with angiographic presence of probable or definite thrombus.&#xD;
&#xD;
         18. Target lesion involves a bifurcation requiring treatment with more than one stent or&#xD;
             pre-dilatation of a side branch &gt;2.0 mm in diameter.&#xD;
&#xD;
         19. Non-target lesion to be treated during the index procedure meets any of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Located within a bypass graft (venous or arterial)&#xD;
&#xD;
               -  Left main location&#xD;
&#xD;
               -  Chronic total occlusion&#xD;
&#xD;
               -  Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1&#xD;
                  stent)&#xD;
&#xD;
               -  Treatment not deemed a clinical angiographic success&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kandzari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cardiac and Vascular Institute Research Foundation</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Healthcare System</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delmarva Heart Research Foundation Inc./Peninsula Regional Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Heart and Vascular Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates Research, LLC</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center/The Christ Hospital Heart and Vascular</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kandzari D, Hearne S, Kumar G, Sachdeva R, Adams G, Blossom B, Dahle T, Sanghvi K, Cohen MG, Imperi G, Riley R, Almonacid AP. Procedural effectiveness with a focused force scoring angioplasty catheter: Procedural and clinical outcomes from the Scoreflex NC trial. Cardiovasc Revasc Med. 2021 Mar 20. pii: S1553-8389(21)00147-0. doi: 10.1016/j.carrev.2021.03.013. [Epub ahead of print]</citation>
    <PMID>33781677</PMID>
  </results_reference>
  <results_reference>
    <citation>Louvard Y, Medina A. Definitions and classifications of bifurcation lesions and treatment. EuroIntervention. 2015;11 Suppl V:V23-6. doi: 10.4244/EIJV11SVA5.</citation>
    <PMID>25983165</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <results_first_submitted>May 4, 2021</results_first_submitted>
  <results_first_submitted_qc>July 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Arteriosclerosis</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03763747/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03763747/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Scoreflex NC Scoring Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter</title>
          <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Scoreflex NC Scoring PTCA Catheter</title>
          <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Lesions</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian/Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian/Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac History</title>
          <description>More than one Cardiac History measure may be reported for each participant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Prior Percutaneous Coronary Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior Coronary Artery Bypass Graft</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Cardiac Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asymptomatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Silent Ischemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Angina</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unstable Angina</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ST-Elevation Myocardial Infarction (STEMI)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Risk Factors</title>
          <description>More than one Cardiac Risk Factor may be reported for each participant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Cigarette Smoking (within 30 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Mellitus (Insulin requiring)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercholesterolemia Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension Requiring Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiographic Characteristics: Vessel Location (Core Lab assessed)</title>
          <description>Analysis is based on the core lab assessed number of lesions (n=221).</description>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <class_list>
            <class>
              <title>Left Anterior Descending Artery (LAD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Circumflex Artery (LCX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Coronary Artery (RCA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Identified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiographic Characteristics: Lesion Location (Core Lab assessed)</title>
          <description>Analysis is based on the core lab assessed anatomic position in the vessel. The total number of lesions assessed is 221.</description>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <class_list>
            <class>
              <title>Ostial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiographic Characteristics: Lesion Characteristics (Core Lab assessed)</title>
          <description>Analysis is based on the core lab assessed number of lesions (n=221).</description>
          <units>Millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <class_list>
            <class>
              <title>Lesion Length</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.37" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal Luminal Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiographic Characteristics: Lesion Characteristics (Core Lab assessed)</title>
          <description>Analysis is based on the core lab assessed number of lesions (n=221).</description>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <class_list>
            <class>
              <title>Moderate/Severe Calcification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate/Severe Tortuosity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Thrombolysis in Myocardial Infarction (TIMI) Flow (Core Lab assessed)</title>
          <description>Analysis is based on the core lab assessed number of lesions (n=221).</description>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <class_list>
            <class>
              <title>0 (no perfusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 (penetration with minimal perfusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (partial perfusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (complete perfusion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiographic Characteristics: Bifurcations, Medina Type (Core Lab assessed)</title>
          <description>The Medina Type is a classification system of the types of significant lesions in the 3 segments of a bifurcation as determined angiographically.&#xD;
A value of 0 or 1 (0 in the absence of significant stenosis and 1 in the presence of a stenosis &gt;50%) is assigned to each of the 3 segments separated in the following order: proximal segment (PM), main distal segment (DM),side branch (SB), the values being separated by commas.(e.g. 1,1,1 would be considered the most complex with disease in all 3 segments.) Medina classification analysis results based upon all angiographic core lab lesions (n=221).</description>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <class_list>
            <class>
              <title>0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0,0,1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0,1,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0,1,1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,0,1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,1,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,1,1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-bifurcation lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Device Procedural Success</title>
        <description>Device procedural success consisting of the following:&#xD;
Successful delivery, inflation, deflation, and withdrawal of the study balloon&#xD;
No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in Thrombolysis In Myocardial Infarction (TIMI) flow from baseline as related to the Scoreflex NC study balloon&#xD;
Final TIMI flow grade of 3 at the conclusion of the percutaneous coronary intervention (PCI) procedure</description>
        <time_frame>Peri-procedural (at Day 0)</time_frame>
        <population>Analysis population consists of intent-to-treat subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Scoreflex NC Scoring PTCA Catheter</title>
            <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Device Procedural Success</title>
          <description>Device procedural success consisting of the following:&#xD;
Successful delivery, inflation, deflation, and withdrawal of the study balloon&#xD;
No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in Thrombolysis In Myocardial Infarction (TIMI) flow from baseline as related to the Scoreflex NC study balloon&#xD;
Final TIMI flow grade of 3 at the conclusion of the percutaneous coronary intervention (PCI) procedure</description>
          <population>Analysis population consists of intent-to-treat subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Angiographic Procedural Success</title>
        <description>Angiographic Procedural Success defined as Final diameter stenosis ≤ 50% in at least one of the Scoreflex NC attempted lesions following completion of the interventional procedure, including adjunctive stenting</description>
        <time_frame>Peri-procedural (at Day 0)</time_frame>
        <population>Analysis population consists of intent-to-treat subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Scoreflex NC Scoring PTCA Catheter</title>
            <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Angiographic Procedural Success</title>
          <description>Angiographic Procedural Success defined as Final diameter stenosis ≤ 50% in at least one of the Scoreflex NC attempted lesions following completion of the interventional procedure, including adjunctive stenting</description>
          <population>Analysis population consists of intent-to-treat subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)</title>
        <description>In-hospital Major Adverse Cardiac Events (MACE), a composite of:&#xD;
All death (cardiac and non-cardiac)&#xD;
Myocardial infarction (MI)&#xD;
Target Lesion Revascularization (TLR), clinically indicated</description>
        <time_frame>Endpoints will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
        <population>Analysis population consists of intent-to-treat subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Scoreflex NC Scoring PTCA Catheter</title>
            <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)</title>
          <description>In-hospital Major Adverse Cardiac Events (MACE), a composite of:&#xD;
All death (cardiac and non-cardiac)&#xD;
Myocardial infarction (MI)&#xD;
Target Lesion Revascularization (TLR), clinically indicated</description>
          <population>Analysis population consists of intent-to-treat subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel</title>
        <description>In-hospital stent thrombosis (ST) within the Target Vessel</description>
        <time_frame>Endpoint will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
        <population>Analysis population consists of intent-to-treat subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Scoreflex NC Scoring PTCA Catheter</title>
            <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel</title>
          <description>In-hospital stent thrombosis (ST) within the Target Vessel</description>
          <population>Analysis population consists of intent-to-treat subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention)</title>
        <description>Clinically Significant Arrhythmias (Requiring Intervention)</description>
        <time_frame>Endpoint will be measured through hospital discharge (expected to be within 24 hours)</time_frame>
        <population>Analysis population consists of intent-to-treat subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Scoreflex NC Scoring PTCA Catheter</title>
            <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention)</title>
          <description>Clinically Significant Arrhythmias (Requiring Intervention)</description>
          <population>Analysis population consists of intent-to-treat subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Scoreflex NC Scoring Catheters That Had Occurrence of Balloon Rupture</title>
        <description>Occurrence of Scoreflex NC Study Balloon rupture</description>
        <time_frame>Peri-procedural</time_frame>
        <population>Analysis population consists of intent-to-treat subject population. Site reported data represented on the use of 239 Scoreflex NC Scoring PTCA catheter study devices.</population>
        <group_list>
          <group group_id="O1">
            <title>Scoreflex NC Scoring PTCA Catheter</title>
            <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Scoreflex NC Scoring Catheters That Had Occurrence of Balloon Rupture</title>
          <description>Occurrence of Scoreflex NC Study Balloon rupture</description>
          <population>Analysis population consists of intent-to-treat subject population. Site reported data represented on the use of 239 Scoreflex NC Scoring PTCA catheter study devices.</population>
          <units>Scoreflex NC Scoring PTCA catheters</units>
          <param>Count of Units</param>
          <units_analyzed>Scoreflex NC Scoring PTCA catheters</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Scoreflex NC Scoring PTCA catheters</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Had Improvement in Minimum Lumen Diameter (MLD) Following Use of Scoreflex NC Catheter (Measured by Quantitative Coronary Angiography (QCA))</title>
        <description>Improvement in Minimum Lumen Diameter (MLD) following use of Scoreflex NC catheter (measured by QCA).&#xD;
Improvement in MLD is defined as MLD post use of Scoreflex as greater than MLD from baseline.</description>
        <time_frame>Peri-procedural</time_frame>
        <population>Analysis population consists of intent-to-treat subject population. Please note that the data for Number of Participants that had Improvement in Minimum Lumen Diameter was not analyzable in 23 patients by the Angiographic Core Lab.</population>
        <group_list>
          <group group_id="O1">
            <title>Scoreflex NC Scoring PTCA Catheter</title>
            <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Had Improvement in Minimum Lumen Diameter (MLD) Following Use of Scoreflex NC Catheter (Measured by Quantitative Coronary Angiography (QCA))</title>
          <description>Improvement in Minimum Lumen Diameter (MLD) following use of Scoreflex NC catheter (measured by QCA).&#xD;
Improvement in MLD is defined as MLD post use of Scoreflex as greater than MLD from baseline.</description>
          <population>Analysis population consists of intent-to-treat subject population. Please note that the data for Number of Participants that had Improvement in Minimum Lumen Diameter was not analyzable in 23 patients by the Angiographic Core Lab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the point of subject enrollment through study completion at hospital discharge (hospital stay expected to be an average of 24 hours).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Scoreflex NC Scoring PTCA Catheter</title>
          <description>Single arm with investigational Scoreflex NC Scoring PTCA catheters&#xD;
Scoreflex NC Scoring PTCA catheter: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Target Lesion Revascularization Clinically Indicated TLR)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction (Non Q-wave)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction (Non Q-wave)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Clinically Significant Arrhythmias (Requiring Intervention)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen M. Rowland, PhD - Vice-President, Research and Development</name_or_title>
      <organization>OrbusNeich</organization>
      <phone>954-730-0711</phone>
      <email>srowland@orbusneich.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

